SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is generating buzz as an early-stage community-driven project with an active developer, attracting attention from investors looking to move beyond typical pump-and-dump cycles. The community is actively pushing for mainstream platform visibility and increased trading volume to support their long-term goal of hitting significant market cap milestones.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is gaining momentum and trending as investors react to a strategic payroll infrastructure partnership with Stellar, fueling optimism for broader institutional adoption. The community is actively discussing the potential for future XRP collaboration and a possible Coinbase listing, with many using the current price consolidation as a strategic accumulation phase.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as investors highlight its ultra-low circulating supply and small market capitalization as key drivers for significant growth potential. The community is actively discussing the token's upside, with many calling for increased volume and exchange listings to catalyze a major breakout.

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

VEIL is trending as community members rally behind its privacy-focused technology on the Base network, often citing support from Coinbase Ventures as a key catalyst. Enthusiasts are actively discussing the project's long-term potential for adoption and its mining and staking features, viewing it as a essential tool for digital sovereignty.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing heightened investor interest driven by a combination of its ongoing strategic pivot into pharmaceutical manufacturing, a fortified balance sheet, and market speculation regarding potential domestic supply chain contracts. Community discussion remains heavily focused on the company's turnaround progress, its status as a potential beneficiary of new pharmaceutical import tariffs, and bullish long-term value projections based on its infrastructure and asset base.

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Grace Therapeutics Inc.

Grace Therapeutics is gaining momentum as investors anticipate the upcoming PDUFA date for its drug candidate GTx-104. The community is focused on the potential for institutional accumulation and the stock's low float, with many discussing the strategic value of the asset as the company nears its regulatory catalyst.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing heightened social media activity and trading volume driven by investor interest in its post-quantum cryptography features and recent institutional developments, including a shift toward US-based operations. The community remains deeply divided, with long-term holders expressing conviction in the project's technology and future adoption, while active traders continue to debate its recent price volatility and past performance relative to broader market trends.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is attracting significant attention as investors track its Phase 2 LOTUS trial progress and potential for its lead asset, AVTX-009, to impact the competitive immunology market. The community is actively discussing recent analyst coverage, including buy ratings and optimistic price targets, while maintaining a cautious dialogue regarding the company's long-term financing needs and historical volatility.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

Procter & Gamble is currently drawing significant attention as investors shift toward defensive, high-quality dividend compounders amid broader market volatility. The community is actively debating whether the stock's current price levels represent a strategic accumulation point for long-term wealth building or a potential value trap as the company navigates ongoing cost-savings initiatives.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is seeing heightened volatility and active call buying as the community debates potential short-squeeze dynamics and the impact of a high short interest against an anticipated operational turnaround. Traders are closely monitoring the stock's price action around critical technical levels, fueled by speculation regarding activist interest and upcoming earnings, while opinions remain sharply divided on the company's long-term sustainability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Semaglutide Ruling Sparks Generic Pharma Boom

… oncology drugs . India's revocation of Novartis … Natco Pharma to launch its version of Roche … Natco Pharma to launch a generic version of Roche … Zydus Lifesciences, Natco Pharma , Alkem Laboratories, and Torrent Pharmaceuticals have developed …

Alkem Laboratories launches semaglutide in India at ₹450 per week, eyes booming weight-loss market

… demand for weight-loss drugs . The patent expiry of semaglutide … active ingredient in blockbuster drugs like Ozempic and Wegovy … to tap the opportunity. Sun Pharmaceutical Industries has launched … 4,200 a month. Glenmark Pharmaceuticals is offering " …

Rs 325–4,200/month: Dr Reddy’s, Sun Pharma, Glenmark kick off generic semaglutide price war

… Reddy’s Laboratories, Sun Pharma , Glenmark Pharmaceuticals , Alkem Laboratories, Zydus Lifesciences … , and Natco Pharma . Eris Lifesciences, which has a … first Indian pharma company to receive approval from the Drugs Controller General …

Alkem Laboratories launches semaglutide in India at Rs 450 per week, eyes booming weight-loss market

Alkem Laboratories has launched a new semaglutide injection in India. This drug targets the growing diabetes and weight loss market. It is available under brand names like Semasize and Obesema. The injection is administered once weekly. Alkem offers a pre-filled pen for a month's dosage at Rs 1,800. This makes the weekly cost Rs 450.

Brief Healthcare: Cadrenal Therapeutics Inc - In December 2025 and more

In this briefing: Cadrenal Therapeutics Inc - In December 2025 Actinogen Medical — XanaMIA passes interim analysis and marches on Alkem Laboratories: Occlutech M&A to Support Medtech Aspiration. Maintain ADD Hybridan Small Cap Feast: 12 February 2026 Vieworks (100120 KQ/Buy)Steady Performance, Attractive Valuation 1. Cadrenal Therapeutics Inc - In December 2025 In December 2025, Cadrenal Therapeutics, Inc. (CVKD) announced it had acquired VLX-1005, a first-in-class, selective 12-lipoxygenase (12-LOX) inhibitor that is being developed for heparin-induced thrombocytopenia (HIT), a rare, immune-mediated thrombotic disorder with high morbidity and mortality. VLX-1005 is designed to address the underlying platelet-driven inflammatory and prothrombotic mechanisms of HIT rather than coagulation alone. The compound has completed Phase 1 clinical development with a favorable safety and pharmacokinetic profile and has generated encouraging Phase 2 proof-of-concept data indicating a potential reduction in thrombotic complications. 2.

Alkem Laboratories Ltd. engages in the development, manufacture, and sale of pharmaceutical products. It produces branded generics, generic drugs, active pharmaceutical ingredient, and nutraceuticals. The company was founded by Samprada Singh and Basudeo Narain Singh on August 8, 1973 and is headquartered in Mumbai, India.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	49.10	--	--	N/A
Q3 '25	57.79	53.19	-7.96%	MISSED
Q2 '25	58.65	63.99	9.11%	BEAT
Q1 '25	45.10	55.60	23.28%	BEAT
Q4 '24	29.27	25.60	-12.55%	MISSED

ALKEM.NSE
Alkem Laboratories Limited

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ALKEM.NSE News

ALKEM.NSEAlkem Laboratories Limited